Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 6,770 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: Glioma Tumor Recurrence, Radiation Necrosis, Primary Brain Tumor
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immunoproliferative Disorder
Interventions: Bacteriophage, rhuCD40L, KLH; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Neoplasms, Neoplasm Metastasis
Interventions: PSC 833, vinblastine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Number of Quit Attempts
Interventions: Self-affirmation induction; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 7,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical and Lumbar Fusion
Interventions: Fortilink IBF System with TETRAfuse Technology; Device
Lead sponsor: RTI Surgical; Industry
Eligibility: Not listed
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Sherman Oaks, California • Lone Tree, Colorado • Boca Raton, Florida + 2 more

Conditions: Focal Dystonia
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions: Epcoritamab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 70
States / cities: Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years and older
Enrollment: 1,091 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions: bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate, vinorelbine tartrate, cyclophosphamide, etoposide phosphate, prednisone, filgrastim, ifosfamide; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 156
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 121 more

Conditions: Malignant Pleural Mesothelioma
Interventions: MORAb-009 (Amatuximab), Pemetrexed, Cisplatin; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Sickle Cell Disease
Interventions: Niacin-ER, Placebo, L-NMMA, Acetylcholine; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 4 Years to 120 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parotid Salivary Dysfunction
Interventions: Gene Transfer, AdhAQP1; Genetic · Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Lung Cancer, Renal Cancer, Adrenal Cancer
Interventions: FPAC; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer Disease
Interventions: bapineuzumab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 164
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more

Conditions: Myelodysplastic Syndrome
Interventions: CC-11006; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Tampa, Florida • Indianapolis, Indiana • Bethesda, Maryland + 4 more

Conditions: HIV, Hematologic Malignancies
Interventions: RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Muscular Dystrophy
Interventions: Omigapil; Drug
Lead sponsor: Santhera Pharmaceuticals; Industry
Eligibility: 5 Years to 16 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Adrenal Hyperplasia
Interventions: Hydrocortisone; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: ctDNA MRD test; Diagnostic Test
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 56
States / cities: Anchorage, Alaska • Palo Alto, California • Torrance, California + 48 more

Conditions: Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
Interventions: Biopsy of Bladder, Biospecimen Collection, Cisplatin, Computed Tomography, Cystoscopy, Durvalumab, Fluorouracil, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Mitomycin, Patient Observation, Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 216
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 153 more

Conditions: Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Interventions: None - Observational Study; Other
Lead sponsor: Tempus AI; Industry
Eligibility: 0 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 13
States / cities: Iowa City, Iowa • Bethesda, Maryland • St Louis, Missouri + 9 more

Conditions: Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis

Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging

Evaluation of the Fortilink IBF System With TETRAfuse Technology

Neurophysiology of Task-Specificity of Focal Hand Dystonia

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Genetic, Brain Structure, and Environmental Effects on ADHD

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Niacin to Improve Blood Flow in People With Sickle Cell Disease

Diagnosis and Treatment of Patients With Cystic Fibrosis

Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer

A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Evaluation for NCI Surgery Branch Clinical Research Protocols